000			03107nam a22004575i 4500
001			60620
005			20200226102325.0
007			cr nn 008mamaa
008			170407s2017 si | s |||| 0|eng d
020			_a9789811035098 _9978-981-10-3509-8
024	7		_a10.1007/978-981-10-3509-8 _2doi
035			_a(DE-He213)978-981-10-3509-8
050		4	_aRC648-665.2
072		7	_aMJGD _2bicssc
072		7	_aMED027000 _2bisacsh
072		7	_aHEA039050 _2bisacsh
082	0	4	_a616.462 _223
082	0	4	_a616.46 _223
100	1		_aStewart, Michael W. _eauthor.
245	1	0	_aDiabetic Retinopathy _h[electronic resource] : _bCurrent Pharmacologic Treatment and Emerging Strategies / _cby Michael W. Stewart.
264		1	_aSingapore : _bSpringer Singapore : _bImprint: Adis, _c2017.
300			_aXIII, 268 p. 61 illus., 48 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_a1. Diabetes and Diabetic Retinopathy: Overview Of A World-Wide Epidemic -- 2. The Diabetic Retina: Anatomy and Pathophysiology -- 3. Treatment of Diabetic Retinopathy: A Historical Perspective -- 4. Targeting Vascular Endothelial Growth Factor -- 5. Corticosteroids: Targeting Multiple Cytokines and Chemokines -- 6. Current Treatment Recommendations -- 7. Vitreolysis: Targeting the Vitreoretinal Interface -- 8. Investigational Medications -- 9. Safety Considerations of Pharmacotherapy -- 10. Socioeconomic Cost of Diabetic Retinopathy and Therapy.
520			_aA well-illustrated and comprehensive analysis of the treatment of diabetic retinopathy, this book covers current treatment options and guidelines, whilst also providing a detailed discussion of emerging therapeutic targets. Existing therapeutic options are covered in depth, with a major focus on anti-vascular endothelial growth factor drugs and sustained release corticosteroids, including a review of trial results supporting current treatment guidelines. The use of agents off-label is also discussed. Controversial topics are discussed in detail with an emphasis on helping the reader make informed decisions, particularly when treating patients for which several treatment approaches may be appropriate because trial data does not clearly define the best option. Emerging therapeutic areas are evaluated, as work continues to identify agents that produce superior morphologic responses and visual acuity gains by targeting other molecules that contribute to diabetic retinopathy. Promising new drugs, targets and delivery systems are identified, and their development analysed.
650		0	_aMedicine.
650		0	_aDiabetes.
650		0	_aOphthalmology.
650	1	4	_aMedicine & Public Health.
650	2	4	_aDiabetes.
650	2	4	_aOphthalmology.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9789811035081
856	4	0	_uhttp://dx.doi.org/10.1007/978-981-10-3509-8
912			_aZDB-2-SME
999			_c1874 _d1874